Intercept Pharmaceuticals Inc Short % of float

What is the Short % of float of Intercept Pharmaceuticals Inc?

The Short % of float of Intercept Pharmaceuticals Inc is 12.40%

What is the definition of Short % of float?



Short percentage of float is the amount of shares being shorted compared to the float expressed as a percentage.

= short interest / float shares

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

Short % of float of companies in the Health Care sector on NASDAQ compared to Intercept Pharmaceuticals Inc

What does Intercept Pharmaceuticals Inc do?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Companies with short % of float similar to Intercept Pharmaceuticals Inc